Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants
Ushma D. Wadia, Madeline M. Ong, Sarah N. Cox, Huong Le et autres
Importance: In February 2025, Australia introduced maternal vaccination with bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) in the National Immunization Program for pregnant individuals from 28 weeks' gestation as the primary, year-round strategy to prevent RSV disease in infants 6 …
au, us (code pays fourni par la source)
4 citations
Archives of Pediatrics and Adolescent Medicine